Fully human Anti-SIGLEC15 Antibody BSI-060T used for solid tumors population groups
Seeking a collaboration opportunity with a company that has a strategic interest in the treatment of solid tumors
Field: Treatment of solid tumors, including metastatic head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, triple-negative breast cancer, endometrial cancer, squamous cell carcinoma, colorectal cancer
Technology and MOA
MOA: blocks the immunosuppressive effect of Siglec-15
Siglec-15 is an immunomodulatory target expressed on a restricted set of myeloid cells in the tumor microenvironment. The drug candidate prevents immune suppression caused by S15 which is done by targeting M2 macrophages, S15-induced myeloid cells and S15-positive tumors. The drug candidate elicits the therapeutic intervention by decreasing inflammatory cytokines associated with enhanced tumor growth, promote T cell proliferation and restore T cell function.
At present, the clinical application of tumor immunotherapy is very effective, which can significantly alleviate and improve the condition of cancer patients. However, for the current mainstream PD-(L)1 antibodies, a considerable part of patients still fail to achieve the expected therapeutic effect. Data from Siglec15’s laboratory studies show that Siglec-15 can regulate immune suppression in a manner independent of the PD-1 / PD-L1 pathway, sustainably inhibit T cell activity, and may meet the main characteristics of normalized immunotherapy. This indicates that anti-siglec15 antibody may have potential for use in patients who do not express PD-L1, and is a relatively safe anti-cancer pathway.
Differentiable treatment with potential to be first/ best in class
BSI-060T is a high-affinity fully human anti-Siglec15 monoclonal antibody with superior bioactivity to the benchmark.
• Colorectal Cancer
• Endometrial Cancer
• Head And Neck Cancer Squamous Cell Carcinoma;
• Merkel Cell Carcinoma
• Non-Small Cell Lung Cancer
• Ovarian Cancer
• Squamous Cell Carcinoma
• Triple-Negative Breast Cancer (TNBC)
Key parameters of fully human anti-Siglec15 (S15) antibody BSI-060T as compared to NC318:
• Exhibits 6-fold higher affinity to huS15 and cyno-S15 than NC318
• Shows superior cellular bioactivity than NC318 (on reversing T cell proliferation inhibition by S15 ex vivo assay)
• In vivo efficacy and PK/PD studies are on-going…
For discussion under CDA.